Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315

Cancer Immunology, Immunotherapy

Volumn 63, Issue 6, 2014, Pages 601-613

  Camilio, Ketil André ^a,b   Berge, Gerd ^b   Ravuri, Chandra Sekhar ^b   Rekdal, Øystein ^a,b   Sveinbjørnsson, Baldur ^b,c  

^a LYTIX BIOPHARMA AS   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Anticancer peptide; B16 melanoma; DAMPs; Immunogenic cell death; Inflammation; Intratumoral treatment

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DACARBAZINE; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOMODULATING AGENT; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; LTX 315; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER REGRESSION; CELL INFILTRATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; EMBRYO; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MELANOMA B16; MOLECULE; MOUSE; NONHUMAN; PARENCHYMA; PLASMA; PRIORITY JOURNAL; PROTEIN SECRETION; SINGLE DRUG DOSE; T LYMPHOCYTE; TUMOR NECROSIS; UPREGULATION;

ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; BLOTTING, WESTERN; CATTLE; CELLS, CULTURED; CYTOKINES; FEMALE; HEMOLYSIS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LACTOFERRIN; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, NUDE; PEPTIDE FRAGMENTS;

EID: 84901642385     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-014-1540-0     Document Type: Article

References (58)

1. Little EG, Eide MJ (2012) Update on the current state of melanoma incidence. Dermatol Clin 30:355-361. doi: 10.1016/j.det.2012.04.001
2. Duran Garcia E, Santolaya R, Requena T (1999) Treatment of malignant melanoma. Ann Pharmacother 33:730-738. doi: 10.1345/aph.18190
3. McNeer G, Das Gupta T (1965) Treatment of malignant melanoma. CA Cancer J Clin 15:229-231. doi: 10.3322/canjclin.15.5.229
4. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N et al (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635-3648
5. Eggermont AM, Robert C (2011) New drugs in melanoma: it's a whole new world. Eur J Cancer 47:2150-2157. doi: 10.1016/j.ejca.2011.06.052
6. Spagnolo F, Queirolo P (2012) Upcoming strategies for the treatment of metastatic melanoma. Arch Dermatol Res 304:177-184. doi: 10.1007/s00403-012- 1223-7
7. Zasloff M (2002) Antimicrobial peptides of multicellular organisms. Nature 415:389-395. doi: 10.1038/415389a
8. Pasupuleti M, Schmidtchen A, Malmsten M (2012) Antimicrobial peptides: key components of the innate immune system. Crit Rev Biotechnol 32:143-171. doi: 10.3109/07388551.2011.594423
9. Hoskin DW, Ramamoorthy A (2008) Studies on anticancer activities of antimicrobial peptides. Biochim Biophys Acta 1778:357-375. doi: 10.1016/j.bbamem.2007.11.008
10. Mader JS, Hoskin DW (2006) Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment. Expert Opin Investig Drugs 15:933-946. doi: 10.1517/13543784.15.8.933
11. Schweizer F (2009) Cationic amphiphilic peptides with cancer-selective toxicity. Eur J Pharmacol 625:190-194. doi: 10.1016/j.ejphar.2009.08.043
12. Riedl S, Zweytick D, Lohner K (2011) Membrane-active host defense peptides - challenges and perspectives for the development of novel anticancer drugs. Chem Phys Lipids 164:766-781. doi: 10.1016/j.chemphyslip.2011.09.004
13. Utsugi T, Schroit AJ, Connor J, Bucana CD, Fidler IJ (1991) Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res 51:3062-3066
14. Marth E, Flaschka G, Stiegler S, Mose JR (1988) Sialic-acid as a marker for differentiation between benign and malignant intracranial tumors. Clin Chim Acta 176:251-257. doi: 10.1016/0009-8981(88)90184-2
15. Fadnes B, Uhlin-Hansen L, Lindin I, Rekdal O (2011) Small lytic peptides escape the inhibitory effect of heparan sulfate on the surface of cancer cells. BMC Cancer 11:116-126. doi: 10.1186/1471-2407-11-116
16. Kleeff J, Ishiwata T, Kumbasar A, Friess H, Buchler MW et al (1998) The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J Clin Invest 102:1662-1673. doi: 10.1172/JCI4105
17. Kozłowska K, Nowak J, Kwiatkowski B, Cichorek M (1999) ESR study of plasmatic membrane of the transplantable melanoma cells in relation to their biological properties. Exp Toxicol Pathol 51:89-92. doi: 10.1016/s0940-2993(99) 80074-8
18. Sok M, Sentjurc M, Schara M (1999) Membrane fluidity characteristics of human lung cancer. Cancer Lett 139:215-220. doi: 10.1016/s0304-3835(99)00044-0
19. Chaudhary J, Munshi M (1995) Scanning electron microscopic analysis of breast aspirates. Cytopathology 6:162-167. doi: 10.1111/j.1365-2303.1995. tb00469.x
20. Domagala W, Koss L (1980) Surface configuration of human tumor cells obtained by fine needle aspiration biopsy. Scan Electron Microsc 3:101-108
21. Johnstone SA, Gelmon K, Mayer LD, Hancock RE, Bally MB (2000) In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines. Anticancer Drug Des 15:151-160
22. Kim S, Kim SS, Bang YJ, Kim SJ, Lee BJ (2003) In vitro activities of native and designed peptide antibiotics against drug sensitive and resistant tumor cell lines. Peptides 24:945-953. doi: 10.1016/s0196-9781(03)00194-3
23. Eliassen LT, Berge G, Sveinbjornsson B, Svendsen JS, Vorland LH et al (2002) Evidence for a direct antitumor mechanism of action of bovine lactoferricin. Anticancer Res 22:2703-2710
24. Eliassen LT, Berge G, Leknessund A, Wikman M, Lindin I et al (2006) The antimicrobial peptide, lactoferricin B, is cytotoxic to neuroblastoma cells in vitro and inhibits xenograft growth in vivo. Int J Cancer 119:493-500. doi: 10.1002/ijc.21886
25. Mader JS, Salsman J, Conrad DM, Hoskin DW (2005) Bovine lactoferricin selectively induces apoptosis in human leukemia and carcinoma cell lines. Mol Cancer Ther 4:612-624. doi: 10.1158/1535-7163.MCT-04-0077
26. Yoo YC, Watanabe R, Koike Y, Mitobe M, Shimazaki K et al (1997) Apoptosis in human leukemic cells induced by lactoferricin, a bovine milk protein-derived peptide: involvement of reactive oxygen species. Biochem Biophys Res Commun 237:624-628. doi: 10.1006/bbrc.1997.7199
27. Yoo YC, Watanabe S, Watanabe R, Hata K, Shimazaki K et al (1997) Bovine lactoferrin and lactoferricin, a peptide derived from bovine lactoferrin, inhibit tumor metastasis in mice. Jpn J Cancer Res 88:184-190
28. Berge G, Eliassen LT, Camilio KA, Bartnes K, Sveinbjornsson B et al (2010) Therapeutic vaccination against a murine lymphoma by intratumoral injection of a cationic anticancer peptide. Cancer Immunol Immunother 59:1285-1294. doi: 10.1007/s00262-010-0857-6
29. Eliassen LT, Haug BE, Berge G, Rekdal O (2003) Enhanced antitumour activity of 15-residue bovine lactoferricin derivatives containing bulky aromatic amino acids and lipophilic N-terminal modifications. J Pept Sci 9:510-517. doi: 10.1002/psc.472
30. Yang N, Lejon T, Rekdal O (2003) Antitumour activity and specificity as a function of substitutions in the lipophilic sector of helical lactoferrin-derived peptide. J Pept Sci 9:300-311. doi: 10.1002/psc.457
31. Yang N, Stensen W, Svendsen JS, Rekdal O (2002) Enhanced antitumor activity and selectivity of lactoferrin-derived peptides. J Pept Res 60:187-197. doi: 10.1034/j.1399-3011.2002.21008.x
32. Yang N, Strom MB, Mekonnen SM, Svendsen JS, Rekdal O (2004) The effects of shortening lactoferrin derived peptides against tumour cells, bacteria and normal human cells. J Pept Sci 10:37-46. doi: 10.1002/psc.470
33. Sen TZ, Jernigan RL, Garnier J, Kloczkowski A (2005) GOR V server for protein secondary structure prediction. Bioinformatics 21:2787-2788. doi: 10.1093/bioinformatics/bti408
34. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63
35. -ΔΔCT method. Methods 25:402-408. doi: 10.1006/meth.2001.1262
36. Zeya HI, Spitznagel JK (1963) Antibacterial and enzymic basic proteins from leukocyte lysosomes: separation and identification. Science 142:1085-1087. doi: 10.1126/science.142.3595.1085
37. Zeya HI, Spitznagel JK (1966) Cationic proteins of polymorphonuclear leukocyte lysosomes I. Resolution of antibacterial and enzymatic activities. J Bacteriol 91:750-754
38. Pereira A, Kerkis A, Hayashi MA, Pereira AS, Silva FS et al (2011) Crotamine toxicity and efficacy in mouse models of melanoma. Expert Opin Investig Drugs 20:1189-1200. doi: 10.1517/13543784.2011.602064
39. Overwijk WW, Restifo NP (2001) B16 as a mouse model for human melanoma. Current PROTOCOLS IN IMMUNOLOGY. Wiley, New York, pp 1-32
40. Barasch A, Epstein JB, Foong WC, Clayman L (2004) Intralesional chemotherapy for head and neck carcinoma: a review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 97:307-311. doi: 10.1016/ S1079210403007236
41. Cornwell DG, Heikkila RE, Bar RS, Biagi GL (1968) Red blood cell lipids and the plasma membrane. J Am Oil Chem Soc 45:297-304. doi: 10.1007/BF02667099
42. Britten CD, Rowinsky EK, Baker SD, Agarwala SS, Eckardt JR et al (1999) A phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. Clin Cancer Res 5:1629-1637
43. Lee SM, Margison GP, Thatcher N, O'Connor PJ, Cooper DP (1994) Formation and loss of O6-methyldeoxyguanosine in human leucocyte DNA following sequential DTIC and fotemustine chemotherapy. Br J Cancer 69:853-857
44. Lens MB, Eisen TG (2003) Systemic chemotherapy in the treatment of malignant melanoma. Expert Opin Pharmacother 4:2205-2211. doi: 10.1517/14656566.4.12.2205
45. Chan JK, Roth J, Oppenheim JJ, Tracey KJ, Vogl T et al (2012) Alarmins: awaiting a clinical response. J Clin Invest 122:2711-2719. doi: 10.1172/JCI62423
46. Pisetsky DS (2014) The translocation of nuclear molecules during inflammation and cell death. Antioxid Redox Signal 20:1117-1125. doi: 10.1089/ars.2012.5143
47. Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E et al (2003) Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 101:2652-2660. doi: 10.1182/blood-2002-05-1300
48. Messmer D, Yang H, Telusma G, Knoll F, Li J et al (2004) High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol 173:307-313
49. DeMarco RA, Fink MP, Lotze MT (2005) Monocytes promote natural killer cell interferon gamma production in response to the endogenous danger signal HMGB1. Mol Immunol 42:433-444. doi: 10.1016/j.molimm.2004.07.023
50. Dinarello CA (2009) Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 27:519-550. doi: 10.1146/annurev.immunol. 021908.132612
51. Nakae S, Asano M, Horai R, Iwakura Y (2001) Interleukin-1β, but not interleukin-1α, is required for T-cell-dependent antibody production. Immunology 104:402-409. doi: 10.1046/j.1365-2567.2001.01337.x
52. H17 and regulatory T cells. Nature 441:235-238. doi: 10.1038/nature04753
53. Chaves F, Teixeira CF, Gutierrez JM (2005) Role of TNF-α, IL-1β and IL-6 in the local tissue damage induced by Bothrops asper snake venom: an experimental assessment in mice. Toxicon 45:171-178. doi: 10.1016/j.toxicon.2004.10.005
54. Biet F, Locht C, Kremer L (2002) Immunoregulatory functions of interleukin 18 and its role in defense against bacterial pathogens. J Mol Med (Berl) 80:147-162. doi: 10.1007/s00109-001-0307-1
55. Hoshino T, Kawase Y, Okamoto M, Yokota K, Yoshino K et al (2001) Cutting edge: IL-18-transgenic mice: in vivo evidence of a broad role for IL-18 in modulating immune function. J Immunol 166:7014-7018
56. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H (2001) Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev 12:53-72. doi: 10.1016/S1359- 6101(00)00015-0
57. Okamura H, Tsutsui H, Komatsu T, Yutsudo M, Hakura A et al (1995) Cloning of a new cytokine that induces IFN-γ production by T-Cells. Nature 378:88-91. doi: 10.1038/378088a0
58. Shaw G, Kamen R (1986) A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 46:659-667. doi: 10.1016/0092-8674(86)90341-7